Today, the FDA announced its Commissioner’s National Priority Voucher program to accelerate the delivery of crucial treatments to the American public.

This program aims to accelerate the drug review process for companies aligned with U.S. national priorities while maintaining the FDA's rigorous standards for safety, efficacy, and quality.

So basically, vaccines that save millions of lives are out, but highly experimental therapies with no long term safety data are in?

Love him or hate him, @DrMakaryFDA is creating a bull market for biotech

Can you also decelerate the mRNA vaccines? Asking for a friend of ours.

At first glance, the FDA’s new “Commissioner’s National Priority Voucher” program sounds like a heroic push to fast-track lifesaving treatments but let’s not ignore the pattern. Every time “acceleration” is promised it tends to benefit pharmaceutical giants more than the public. Historically, similar programs like the Priority Review Voucher system have been exploited by drug companies to rush products through approval, sometimes with limited safety data. A 2017 BMJ analysis showed that many fast-tracked drugs were approved on the basis of surrogate markers, not actual clinical outcomes meaning we’re green-lighting treatments without fully understanding if they save lives or just make headlines. Subscribe to our free newsletter [ for weekly deep dives into more insights like this.

Approve NWBO!

The FDA approval of metformin as treatment for type II diabetes took about 40 years too long..

Thank you and your team for this long overdue new program! What a tremendous gift to patients everywhere. ImmunityBio's BioShield (Anktiva) is a must approval to end cancer as we know. Each page represents one patient requesting access to BioShield (Anktiva). Literally, thousands. Lead the way! @DrPatSoonShiong @ImmunityBio

Safety should be a priority over expedited approval…👇

So Operation Warp Speed for everything. That worked out well last time